早期达雷妥尤单抗治疗改善新诊断多发性骨髓瘤合并肾损伤住院患者的肾脏结局
该研究描述20例新诊断多发性骨髓瘤合并急性肾损伤(中位肌酐6.5 mg/dL)患者接受以达雷妥尤单抗为基础治疗的效果。全部患者在第一周期内血清游离轻链(sFLC)降低≥50%,中位时间3天;3个月总体肾脏缓解率85%,其中完全缓解50%、部分缓解10%、轻微缓解25%。中位随访25个月,无进展生存期46.5个月,2年总生存率83.7%。
要点
- 全部患者第一周期内sFLC降低≥50%,中位时间3天。
- 3个月总体肾脏缓解率85%,完全缓解占50%。
- 初始需透析的9例中,3个月和12个月分别有4/7和6/7摆脱透析。
核心结论
- 在新诊断多发性骨髓瘤合并急性肾损伤患者中早期启动以达雷妥尤单抗为基础的治疗可快速显著降低sFLC、改善肾脏结局,并提供一种无需血浆置换的方法。
研究设计与样本
- 描述20例因新诊断多发性骨髓瘤合并急性肾损伤住院患者接受以达雷妥尤单抗为基础治疗的效果,中位肌酐6.5 mg/dL。
主要发现
- 全部患者(100%)在第一周期内sFLC降低≥50%,中位时间3天(95%CI 3-7)。
- 17例中15例(88%)在1周期治疗后sFLC降至≤500 mg/L,中位时间14.5天(95%CI 9-49)。
- 3个月总体肾脏缓解率85%(n=17),完全缓解50%(n=10)、部分缓解10%(n=2)、轻微缓解25%(n=5)。
- 初始需透析的9例中,3个月时7例中4例(57.1%)、12个月时7例中6例(85.7%)摆脱透析。
- 血液学总体缓解率100%,其中非常好的部分缓解(VGPR)90%;中位随访25个月,无进展生存期46.5个月(95%CI 11.9至未达到),2年总生存率83.7%(95%CI 68.4-100)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe the effects of daratumumab-based therapy in 20 patients admitted with a new diagnosis of MM and AKI with a median creatinine of 6.5 mg/dL. All patients (100%) achieved serum free light chain (sFLC) reduction ≥50% within the first cycle, with a median time to sFLC reduction ≥50% of 3 days (95% confidence interval [CI], 3-7). Of 17 patients, 15 (88%) achieved sFLC reduction ≤500 mg/L after 1 cycle of treatment. The median time to sFLC reduction ≤500 mg/L was 14.5 days (95% CI, 9-49). The overall renal response at 3 months was 85% (n = 17), with complete, partial, and minor responses in 50% (n = 10), 10% (n = 2), and 25% (n = 5), respectively. Of the 9 patients who required dialysis at presentation, 4 of 7 (57.1%) and 6 of 7 (85.7%) were dialysis independent at 3 and 12 months, respectively. Hematologic overall response rate was 100%, with very good partial response (VGPR) in 90%. With a median follow-up of 25 months, progression-free survival was 46.5 months (95% CI, 11.9 to not reached), and the 2-year overall survival was 83.7% (95% CI, 68.4-100). These findings highlight the importance of early initiation of daratumumab-based treatment in patients with MM and AKI to induce rapid and significant reductions in sFLCs, improve renal outcomes, and provide an approach without plasmapheresis.
引用
- Kim EB, Malespini JE, Lei M, et al. Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury. Blood Adv. 2025. PMID: 40085948. doi:10.1182/bloodadvances.2025015901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。